Found 90 with Last Name = 'kabro' and Initial = 'a' 
Affinity DataIC50: 15nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 24nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 29nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 33nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 36nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 41nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 42nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 52nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 60nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 60nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 69nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 71nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 75nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 78nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
3D Structure (crystal)TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 86nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 90nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 95nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 102nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 102nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 112nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 128nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 133nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 135nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 138nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 156nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 189nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 215nMAssay Description:Inhibition of CDK12/cyclin K (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 284nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 286nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 299nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 347nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 414nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-T1/Cyclin-dependent kinase 9(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 430nMAssay Description:Inhibition of CDK9/cyclin T1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Homo sapiens (Human))
Syros Pharmaceuticals
Curated by ChEMBL
Syros Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 460nMAssay Description:Inhibition of CDK2/cyclin E1 (unknown origin) using 5-FAM-labeled peptide as substrate in presence of ATP by mobility shift assayMore data for this Ligand-Target Pair
Affinity DataIC50: 550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: 550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: 550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies (Grand Island, N.Y.) using their commercially available Adapta kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: 550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
Affinity DataIC50: 550nMAssay Description:Compounds of the invention were assayed for CDK7 activity at Life Technologies(Grand Island, N.Y.) using their commercially available AdaptaŽ kinase ...More data for this Ligand-Target Pair
